Avesta Bio to launch 8 drugs by '12
P B Jayakumar / Mumbai September 12, 2008, 0:42 IST Avesta Biotherapeutics and Research (ABRPL), the 50:50 joint venture between Cipla group company Meditab Specialities and Bangalore-based Avestha Gengraine Technologies (Avesthagen), is targeting to launch about eight high-value, bio-similar or copied versions of off-patent biotech drugs before 2012. ABRPL is working on developing drugs for anaemia, cancer and arthritis, said Bruce Murdoch, chief business officer, Avesthagen.